nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Clonidine—SLC22A3—coronary artery disease	0.00246	1	CrCbGaD
Apraclonidine—Somnolence—Furosemide—coronary artery disease	0.000385	0.000586	CcSEcCtD
Apraclonidine—Syncope—Timolol—coronary artery disease	0.000385	0.000586	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Perindopril—coronary artery disease	0.000385	0.000586	CcSEcCtD
Apraclonidine—Diarrhoea—Eplerenone—coronary artery disease	0.000384	0.000585	CcSEcCtD
Apraclonidine—Fatigue—Perindopril—coronary artery disease	0.000384	0.000585	CcSEcCtD
Apraclonidine—Pain—Perindopril—coronary artery disease	0.000381	0.00058	CcSEcCtD
Apraclonidine—Constipation—Perindopril—coronary artery disease	0.000381	0.00058	CcSEcCtD
Apraclonidine—Vomiting—Fenofibrate—coronary artery disease	0.000381	0.00058	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Losartan—coronary artery disease	0.000381	0.00058	CcSEcCtD
Apraclonidine—Hypersensitivity—Valsartan—coronary artery disease	0.000381	0.00058	CcSEcCtD
Apraclonidine—Abdominal pain—Trandolapril—coronary artery disease	0.00038	0.000578	CcSEcCtD
Apraclonidine—Dizziness—Ezetimibe—coronary artery disease	0.00038	0.000578	CcSEcCtD
Apraclonidine—Palpitations—Timolol—coronary artery disease	0.000379	0.000577	CcSEcCtD
Apraclonidine—Abdominal pain—Enalapril—coronary artery disease	0.000378	0.000576	CcSEcCtD
Apraclonidine—Feeling abnormal—Captopril—coronary artery disease	0.000378	0.000576	CcSEcCtD
Apraclonidine—Insomnia—Losartan—coronary artery disease	0.000378	0.000575	CcSEcCtD
Apraclonidine—Dermatitis—Fenofibrate—coronary artery disease	0.000378	0.000574	CcSEcCtD
Apraclonidine—Headache—Fenofibrate—coronary artery disease	0.000375	0.000571	CcSEcCtD
Apraclonidine—Vision blurred—Lisinopril—coronary artery disease	0.000375	0.000571	CcSEcCtD
Apraclonidine—Paraesthesia—Losartan—coronary artery disease	0.000375	0.000571	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Captopril—coronary artery disease	0.000375	0.000571	CcSEcCtD
Apraclonidine—Vomiting—Clopidogrel—coronary artery disease	0.000375	0.00057	CcSEcCtD
Apraclonidine—Diarrhoea—Simvastatin—coronary artery disease	0.000375	0.00057	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Furosemide—coronary artery disease	0.000374	0.000569	CcSEcCtD
Apraclonidine—Chest pain—Ramipril—coronary artery disease	0.000374	0.000569	CcSEcCtD
Apraclonidine—Myalgia—Ramipril—coronary artery disease	0.000374	0.000569	CcSEcCtD
Apraclonidine—Fatigue—Furosemide—coronary artery disease	0.000374	0.000568	CcSEcCtD
Apraclonidine—Abdominal pain—Telmisartan—coronary artery disease	0.000373	0.000568	CcSEcCtD
Apraclonidine—Dyspnoea—Losartan—coronary artery disease	0.000373	0.000567	CcSEcCtD
Apraclonidine—Vomiting—Lovastatin—coronary artery disease	0.000372	0.000566	CcSEcCtD
Apraclonidine—Somnolence—Losartan—coronary artery disease	0.000372	0.000566	CcSEcCtD
Apraclonidine—Dizziness—Eplerenone—coronary artery disease	0.000372	0.000565	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Ramipril—coronary artery disease	0.000371	0.000565	CcSEcCtD
Apraclonidine—Dermatitis—Clopidogrel—coronary artery disease	0.000371	0.000565	CcSEcCtD
Apraclonidine—Asthenia—Valsartan—coronary artery disease	0.000371	0.000564	CcSEcCtD
Apraclonidine—Pain—Furosemide—coronary artery disease	0.000371	0.000564	CcSEcCtD
Apraclonidine—Constipation—Furosemide—coronary artery disease	0.000371	0.000564	CcSEcCtD
Apraclonidine—Hypersensitivity—Niacin—coronary artery disease	0.00037	0.000563	CcSEcCtD
Apraclonidine—Ill-defined disorder—Lisinopril—coronary artery disease	0.00037	0.000562	CcSEcCtD
Apraclonidine—Discomfort—Ramipril—coronary artery disease	0.000369	0.000562	CcSEcCtD
Apraclonidine—Asthenia—Olmesartan—coronary artery disease	0.000369	0.000562	CcSEcCtD
Apraclonidine—Headache—Clopidogrel—coronary artery disease	0.000369	0.000562	CcSEcCtD
Apraclonidine—Dermatitis—Lovastatin—coronary artery disease	0.000369	0.000561	CcSEcCtD
Apraclonidine—Feeling abnormal—Perindopril—coronary artery disease	0.000367	0.000559	CcSEcCtD
Apraclonidine—Headache—Lovastatin—coronary artery disease	0.000367	0.000558	CcSEcCtD
Apraclonidine—Pruritus—Valsartan—coronary artery disease	0.000366	0.000556	CcSEcCtD
Apraclonidine—Dry mouth—Ramipril—coronary artery disease	0.000366	0.000556	CcSEcCtD
Apraclonidine—Chest pain—Timolol—coronary artery disease	0.000366	0.000556	CcSEcCtD
Apraclonidine—Myalgia—Timolol—coronary artery disease	0.000366	0.000556	CcSEcCtD
Apraclonidine—Vomiting—Ezetimibe—coronary artery disease	0.000365	0.000555	CcSEcCtD
Apraclonidine—Hypersensitivity—Pravastatin—coronary artery disease	0.000365	0.000555	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Perindopril—coronary artery disease	0.000364	0.000555	CcSEcCtD
Apraclonidine—Pruritus—Olmesartan—coronary artery disease	0.000364	0.000554	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Timolol—coronary artery disease	0.000363	0.000552	CcSEcCtD
Apraclonidine—Abdominal pain—Captopril—coronary artery disease	0.000363	0.000552	CcSEcCtD
Apraclonidine—Dizziness—Simvastatin—coronary artery disease	0.000362	0.000551	CcSEcCtD
Apraclonidine—Dermatitis—Ezetimibe—coronary artery disease	0.000362	0.00055	CcSEcCtD
Apraclonidine—Discomfort—Timolol—coronary artery disease	0.000361	0.00055	CcSEcCtD
Apraclonidine—Asthenia—Niacin—coronary artery disease	0.000361	0.000549	CcSEcCtD
Apraclonidine—Fatigue—Losartan—coronary artery disease	0.00036	0.000548	CcSEcCtD
Apraclonidine—Headache—Ezetimibe—coronary artery disease	0.00036	0.000547	CcSEcCtD
Apraclonidine—Malaise—Lisinopril—coronary artery disease	0.000359	0.000547	CcSEcCtD
Apraclonidine—Oedema—Ramipril—coronary artery disease	0.000358	0.000545	CcSEcCtD
Apraclonidine—Dry mouth—Timolol—coronary artery disease	0.000358	0.000544	CcSEcCtD
Apraclonidine—Pain—Losartan—coronary artery disease	0.000358	0.000544	CcSEcCtD
Apraclonidine—Constipation—Losartan—coronary artery disease	0.000358	0.000544	CcSEcCtD
Apraclonidine—Syncope—Lisinopril—coronary artery disease	0.000357	0.000544	CcSEcCtD
Apraclonidine—Vomiting—Eplerenone—coronary artery disease	0.000357	0.000544	CcSEcCtD
Apraclonidine—Feeling abnormal—Furosemide—coronary artery disease	0.000357	0.000543	CcSEcCtD
Apraclonidine—Nausea—Fenofibrate—coronary artery disease	0.000356	0.000542	CcSEcCtD
Apraclonidine—Pruritus—Niacin—coronary artery disease	0.000356	0.000541	CcSEcCtD
Apraclonidine—Asthenia—Pravastatin—coronary artery disease	0.000355	0.00054	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Furosemide—coronary artery disease	0.000354	0.000539	CcSEcCtD
Apraclonidine—Hypersensitivity—Trandolapril—coronary artery disease	0.000354	0.000539	CcSEcCtD
Apraclonidine—Dermatitis—Eplerenone—coronary artery disease	0.000354	0.000538	CcSEcCtD
Apraclonidine—Diarrhoea—Valsartan—coronary artery disease	0.000354	0.000538	CcSEcCtD
Apraclonidine—Hypersensitivity—Enalapril—coronary artery disease	0.000353	0.000537	CcSEcCtD
Apraclonidine—Abdominal pain—Perindopril—coronary artery disease	0.000352	0.000536	CcSEcCtD
Apraclonidine—Palpitations—Lisinopril—coronary artery disease	0.000352	0.000536	CcSEcCtD
Apraclonidine—Diarrhoea—Olmesartan—coronary artery disease	0.000352	0.000536	CcSEcCtD
Apraclonidine—Headache—Eplerenone—coronary artery disease	0.000352	0.000536	CcSEcCtD
Apraclonidine—Nervous system disorder—Ramipril—coronary artery disease	0.000352	0.000535	CcSEcCtD
Apraclonidine—Oedema—Timolol—coronary artery disease	0.00035	0.000533	CcSEcCtD
Apraclonidine—Pruritus—Pravastatin—coronary artery disease	0.00035	0.000533	CcSEcCtD
Apraclonidine—Nausea—Clopidogrel—coronary artery disease	0.00035	0.000532	CcSEcCtD
Apraclonidine—Skin disorder—Ramipril—coronary artery disease	0.000348	0.00053	CcSEcCtD
Apraclonidine—Infection—Timolol—coronary artery disease	0.000348	0.00053	CcSEcCtD
Apraclonidine—Vomiting—Simvastatin—coronary artery disease	0.000348	0.00053	CcSEcCtD
Apraclonidine—Hypersensitivity—Telmisartan—coronary artery disease	0.000348	0.000529	CcSEcCtD
Apraclonidine—Nausea—Lovastatin—coronary artery disease	0.000348	0.000529	CcSEcCtD
Apraclonidine—Dermatitis—Simvastatin—coronary artery disease	0.000345	0.000525	CcSEcCtD
Apraclonidine—Asthenia—Trandolapril—coronary artery disease	0.000345	0.000525	CcSEcCtD
Apraclonidine—Feeling abnormal—Losartan—coronary artery disease	0.000345	0.000524	CcSEcCtD
Apraclonidine—Diarrhoea—Niacin—coronary artery disease	0.000344	0.000523	CcSEcCtD
Apraclonidine—Nervous system disorder—Timolol—coronary artery disease	0.000344	0.000523	CcSEcCtD
Apraclonidine—Asthenia—Enalapril—coronary artery disease	0.000343	0.000523	CcSEcCtD
Apraclonidine—Headache—Simvastatin—coronary artery disease	0.000343	0.000522	CcSEcCtD
Apraclonidine—Abdominal pain—Furosemide—coronary artery disease	0.000343	0.000521	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Losartan—coronary artery disease	0.000342	0.00052	CcSEcCtD
Apraclonidine—Dizziness—Valsartan—coronary artery disease	0.000342	0.00052	CcSEcCtD
Apraclonidine—Nausea—Ezetimibe—coronary artery disease	0.000341	0.000519	CcSEcCtD
Apraclonidine—Skin disorder—Timolol—coronary artery disease	0.00034	0.000518	CcSEcCtD
Apraclonidine—Dizziness—Olmesartan—coronary artery disease	0.00034	0.000518	CcSEcCtD
Apraclonidine—Pruritus—Trandolapril—coronary artery disease	0.00034	0.000517	CcSEcCtD
Apraclonidine—Chest pain—Lisinopril—coronary artery disease	0.000339	0.000516	CcSEcCtD
Apraclonidine—Myalgia—Lisinopril—coronary artery disease	0.000339	0.000516	CcSEcCtD
Apraclonidine—Asthenia—Telmisartan—coronary artery disease	0.000339	0.000515	CcSEcCtD
Apraclonidine—Pruritus—Enalapril—coronary artery disease	0.000339	0.000515	CcSEcCtD
Apraclonidine—Diarrhoea—Pravastatin—coronary artery disease	0.000339	0.000515	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—coronary artery disease	0.000337	0.000512	CcSEcCtD
Apraclonidine—Discomfort—Lisinopril—coronary artery disease	0.000335	0.00051	CcSEcCtD
Apraclonidine—Pruritus—Telmisartan—coronary artery disease	0.000334	0.000508	CcSEcCtD
Apraclonidine—Nausea—Eplerenone—coronary artery disease	0.000334	0.000508	CcSEcCtD
Apraclonidine—Dizziness—Niacin—coronary artery disease	0.000332	0.000506	CcSEcCtD
Apraclonidine—Dry mouth—Lisinopril—coronary artery disease	0.000332	0.000505	CcSEcCtD
Apraclonidine—Abdominal pain—Losartan—coronary artery disease	0.00033	0.000503	CcSEcCtD
Apraclonidine—Asthenia—Captopril—coronary artery disease	0.000329	0.000501	CcSEcCtD
Apraclonidine—Diarrhoea—Trandolapril—coronary artery disease	0.000329	0.0005	CcSEcCtD
Apraclonidine—Vomiting—Valsartan—coronary artery disease	0.000329	0.0005	CcSEcCtD
Apraclonidine—Diarrhoea—Enalapril—coronary artery disease	0.000327	0.000498	CcSEcCtD
Apraclonidine—Dizziness—Pravastatin—coronary artery disease	0.000327	0.000498	CcSEcCtD
Apraclonidine—Vomiting—Olmesartan—coronary artery disease	0.000327	0.000498	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Ramipril—coronary artery disease	0.000327	0.000497	CcSEcCtD
Apraclonidine—Dermatitis—Valsartan—coronary artery disease	0.000326	0.000495	CcSEcCtD
Apraclonidine—Nausea—Simvastatin—coronary artery disease	0.000325	0.000495	CcSEcCtD
Apraclonidine—Oedema—Lisinopril—coronary artery disease	0.000325	0.000495	CcSEcCtD
Apraclonidine—Pruritus—Captopril—coronary artery disease	0.000325	0.000494	CcSEcCtD
Apraclonidine—Insomnia—Ramipril—coronary artery disease	0.000324	0.000493	CcSEcCtD
Apraclonidine—Dermatitis—Olmesartan—coronary artery disease	0.000324	0.000493	CcSEcCtD
Apraclonidine—Headache—Valsartan—coronary artery disease	0.000324	0.000493	CcSEcCtD
Apraclonidine—Diarrhoea—Telmisartan—coronary artery disease	0.000323	0.000492	CcSEcCtD
Apraclonidine—Infection—Lisinopril—coronary artery disease	0.000323	0.000491	CcSEcCtD
Apraclonidine—Headache—Olmesartan—coronary artery disease	0.000322	0.00049	CcSEcCtD
Apraclonidine—Paraesthesia—Ramipril—coronary artery disease	0.000322	0.00049	CcSEcCtD
Apraclonidine—Asthenia—Perindopril—coronary artery disease	0.00032	0.000487	CcSEcCtD
Apraclonidine—Dyspnoea—Ramipril—coronary artery disease	0.00032	0.000486	CcSEcCtD
Apraclonidine—Vomiting—Niacin—coronary artery disease	0.00032	0.000486	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Timolol—coronary artery disease	0.000319	0.000486	CcSEcCtD
Apraclonidine—Hypersensitivity—Furosemide—coronary artery disease	0.000319	0.000486	CcSEcCtD
Apraclonidine—Somnolence—Ramipril—coronary artery disease	0.000319	0.000485	CcSEcCtD
Apraclonidine—Dizziness—Trandolapril—coronary artery disease	0.000318	0.000484	CcSEcCtD
Apraclonidine—Insomnia—Timolol—coronary artery disease	0.000317	0.000482	CcSEcCtD
Apraclonidine—Dermatitis—Niacin—coronary artery disease	0.000317	0.000482	CcSEcCtD
Apraclonidine—Dizziness—Enalapril—coronary artery disease	0.000317	0.000482	CcSEcCtD
Apraclonidine—Skin disorder—Lisinopril—coronary artery disease	0.000316	0.000481	CcSEcCtD
Apraclonidine—Pruritus—Perindopril—coronary artery disease	0.000315	0.00048	CcSEcCtD
Apraclonidine—Headache—Niacin—coronary artery disease	0.000315	0.000479	CcSEcCtD
Apraclonidine—Paraesthesia—Timolol—coronary artery disease	0.000315	0.000479	CcSEcCtD
Apraclonidine—Vomiting—Pravastatin—coronary artery disease	0.000315	0.000479	CcSEcCtD
Apraclonidine—Diarrhoea—Captopril—coronary artery disease	0.000314	0.000478	CcSEcCtD
Apraclonidine—Dyspnoea—Timolol—coronary artery disease	0.000312	0.000475	CcSEcCtD
Apraclonidine—Dizziness—Telmisartan—coronary artery disease	0.000312	0.000475	CcSEcCtD
Apraclonidine—Dermatitis—Pravastatin—coronary artery disease	0.000312	0.000474	CcSEcCtD
Apraclonidine—Somnolence—Timolol—coronary artery disease	0.000312	0.000474	CcSEcCtD
Apraclonidine—Asthenia—Furosemide—coronary artery disease	0.000311	0.000473	CcSEcCtD
Apraclonidine—Headache—Pravastatin—coronary artery disease	0.00031	0.000472	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Ramipril—coronary artery disease	0.000309	0.000471	CcSEcCtD
Apraclonidine—Fatigue—Ramipril—coronary artery disease	0.000309	0.00047	CcSEcCtD
Apraclonidine—Hypersensitivity—Losartan—coronary artery disease	0.000308	0.000469	CcSEcCtD
Apraclonidine—Nausea—Valsartan—coronary artery disease	0.000307	0.000467	CcSEcCtD
Apraclonidine—Pruritus—Furosemide—coronary artery disease	0.000307	0.000466	CcSEcCtD
Apraclonidine—Constipation—Ramipril—coronary artery disease	0.000307	0.000466	CcSEcCtD
Apraclonidine—Nausea—Olmesartan—coronary artery disease	0.000306	0.000465	CcSEcCtD
Apraclonidine—Vomiting—Trandolapril—coronary artery disease	0.000306	0.000465	CcSEcCtD
Apraclonidine—Diarrhoea—Perindopril—coronary artery disease	0.000305	0.000464	CcSEcCtD
Apraclonidine—Vomiting—Enalapril—coronary artery disease	0.000304	0.000463	CcSEcCtD
Apraclonidine—Dizziness—Captopril—coronary artery disease	0.000304	0.000462	CcSEcCtD
Apraclonidine—Dermatitis—Trandolapril—coronary artery disease	0.000303	0.000461	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Timolol—coronary artery disease	0.000303	0.00046	CcSEcCtD
Apraclonidine—Fatigue—Timolol—coronary artery disease	0.000302	0.00046	CcSEcCtD
Apraclonidine—Dermatitis—Enalapril—coronary artery disease	0.000302	0.000459	CcSEcCtD
Apraclonidine—Headache—Trandolapril—coronary artery disease	0.000301	0.000458	CcSEcCtD
Apraclonidine—Vomiting—Telmisartan—coronary artery disease	0.0003	0.000457	CcSEcCtD
Apraclonidine—Asthenia—Losartan—coronary artery disease	0.0003	0.000456	CcSEcCtD
Apraclonidine—Headache—Enalapril—coronary artery disease	0.0003	0.000456	CcSEcCtD
Apraclonidine—Pain—Timolol—coronary artery disease	0.0003	0.000456	CcSEcCtD
Apraclonidine—Nausea—Niacin—coronary artery disease	0.000299	0.000454	CcSEcCtD
Apraclonidine—Dermatitis—Telmisartan—coronary artery disease	0.000297	0.000453	CcSEcCtD
Apraclonidine—Diarrhoea—Furosemide—coronary artery disease	0.000296	0.000451	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Lisinopril—coronary artery disease	0.000296	0.000451	CcSEcCtD
Apraclonidine—Pruritus—Losartan—coronary artery disease	0.000296	0.00045	CcSEcCtD
Apraclonidine—Headache—Telmisartan—coronary artery disease	0.000296	0.00045	CcSEcCtD
Apraclonidine—Feeling abnormal—Ramipril—coronary artery disease	0.000295	0.000449	CcSEcCtD
Apraclonidine—Dizziness—Perindopril—coronary artery disease	0.000295	0.000448	CcSEcCtD
Apraclonidine—Insomnia—Lisinopril—coronary artery disease	0.000294	0.000447	CcSEcCtD
Apraclonidine—Nausea—Pravastatin—coronary artery disease	0.000294	0.000447	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Ramipril—coronary artery disease	0.000293	0.000446	CcSEcCtD
Apraclonidine—Paraesthesia—Lisinopril—coronary artery disease	0.000292	0.000444	CcSEcCtD
Apraclonidine—Vomiting—Captopril—coronary artery disease	0.000292	0.000444	CcSEcCtD
Apraclonidine—Dyspnoea—Lisinopril—coronary artery disease	0.00029	0.000441	CcSEcCtD
Apraclonidine—Dermatitis—Captopril—coronary artery disease	0.000289	0.00044	CcSEcCtD
Apraclonidine—Somnolence—Lisinopril—coronary artery disease	0.000289	0.00044	CcSEcCtD
Apraclonidine—Feeling abnormal—Timolol—coronary artery disease	0.000289	0.000439	CcSEcCtD
Apraclonidine—Headache—Captopril—coronary artery disease	0.000288	0.000438	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Timolol—coronary artery disease	0.000287	0.000436	CcSEcCtD
Apraclonidine—Dizziness—Furosemide—coronary artery disease	0.000287	0.000436	CcSEcCtD
Apraclonidine—Diarrhoea—Losartan—coronary artery disease	0.000286	0.000435	CcSEcCtD
Apraclonidine—Nausea—Trandolapril—coronary artery disease	0.000285	0.000434	CcSEcCtD
Apraclonidine—Nausea—Enalapril—coronary artery disease	0.000284	0.000433	CcSEcCtD
Apraclonidine—Vomiting—Perindopril—coronary artery disease	0.000283	0.000431	CcSEcCtD
Apraclonidine—Abdominal pain—Ramipril—coronary artery disease	0.000283	0.000431	CcSEcCtD
Apraclonidine—Dermatitis—Perindopril—coronary artery disease	0.000281	0.000427	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Lisinopril—coronary artery disease	0.000281	0.000427	CcSEcCtD
Apraclonidine—Nausea—Telmisartan—coronary artery disease	0.00028	0.000427	CcSEcCtD
Apraclonidine—Fatigue—Lisinopril—coronary artery disease	0.00028	0.000426	CcSEcCtD
Apraclonidine—Headache—Perindopril—coronary artery disease	0.000279	0.000425	CcSEcCtD
Apraclonidine—Pain—Lisinopril—coronary artery disease	0.000278	0.000423	CcSEcCtD
Apraclonidine—Constipation—Lisinopril—coronary artery disease	0.000278	0.000423	CcSEcCtD
Apraclonidine—Abdominal pain—Timolol—coronary artery disease	0.000277	0.000422	CcSEcCtD
Apraclonidine—Dizziness—Losartan—coronary artery disease	0.000276	0.000421	CcSEcCtD
Apraclonidine—Vomiting—Furosemide—coronary artery disease	0.000276	0.000419	CcSEcCtD
Apraclonidine—Dermatitis—Furosemide—coronary artery disease	0.000273	0.000415	CcSEcCtD
Apraclonidine—Nausea—Captopril—coronary artery disease	0.000273	0.000415	CcSEcCtD
Apraclonidine—Headache—Furosemide—coronary artery disease	0.000271	0.000413	CcSEcCtD
Apraclonidine—Feeling abnormal—Lisinopril—coronary artery disease	0.000268	0.000408	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Lisinopril—coronary artery disease	0.000266	0.000405	CcSEcCtD
Apraclonidine—Vomiting—Losartan—coronary artery disease	0.000266	0.000404	CcSEcCtD
Apraclonidine—Nausea—Perindopril—coronary artery disease	0.000265	0.000403	CcSEcCtD
Apraclonidine—Hypersensitivity—Ramipril—coronary artery disease	0.000264	0.000402	CcSEcCtD
Apraclonidine—Dermatitis—Losartan—coronary artery disease	0.000263	0.000401	CcSEcCtD
Apraclonidine—Headache—Losartan—coronary artery disease	0.000262	0.000399	CcSEcCtD
Apraclonidine—Hypersensitivity—Timolol—coronary artery disease	0.000258	0.000393	CcSEcCtD
Apraclonidine—Nausea—Furosemide—coronary artery disease	0.000257	0.000392	CcSEcCtD
Apraclonidine—Asthenia—Ramipril—coronary artery disease	0.000257	0.000391	CcSEcCtD
Apraclonidine—Abdominal pain—Lisinopril—coronary artery disease	0.000257	0.000391	CcSEcCtD
Apraclonidine—Pruritus—Ramipril—coronary artery disease	0.000254	0.000386	CcSEcCtD
Apraclonidine—Asthenia—Timolol—coronary artery disease	0.000251	0.000383	CcSEcCtD
Apraclonidine—Nausea—Losartan—coronary artery disease	0.000248	0.000378	CcSEcCtD
Apraclonidine—Pruritus—Timolol—coronary artery disease	0.000248	0.000377	CcSEcCtD
Apraclonidine—Diarrhoea—Ramipril—coronary artery disease	0.000245	0.000373	CcSEcCtD
Apraclonidine—Diarrhoea—Timolol—coronary artery disease	0.00024	0.000365	CcSEcCtD
Apraclonidine—Hypersensitivity—Lisinopril—coronary artery disease	0.00024	0.000364	CcSEcCtD
Apraclonidine—Dizziness—Ramipril—coronary artery disease	0.000237	0.000361	CcSEcCtD
Apraclonidine—Asthenia—Lisinopril—coronary artery disease	0.000233	0.000355	CcSEcCtD
Apraclonidine—Dizziness—Timolol—coronary artery disease	0.000232	0.000353	CcSEcCtD
Apraclonidine—Pruritus—Lisinopril—coronary artery disease	0.00023	0.00035	CcSEcCtD
Apraclonidine—Vomiting—Ramipril—coronary artery disease	0.000228	0.000347	CcSEcCtD
Apraclonidine—Dermatitis—Ramipril—coronary artery disease	0.000226	0.000344	CcSEcCtD
Apraclonidine—Headache—Ramipril—coronary artery disease	0.000225	0.000342	CcSEcCtD
Apraclonidine—Vomiting—Timolol—coronary artery disease	0.000223	0.000339	CcSEcCtD
Apraclonidine—Diarrhoea—Lisinopril—coronary artery disease	0.000222	0.000338	CcSEcCtD
Apraclonidine—Dermatitis—Timolol—coronary artery disease	0.000221	0.000336	CcSEcCtD
Apraclonidine—Headache—Timolol—coronary artery disease	0.00022	0.000334	CcSEcCtD
Apraclonidine—Dizziness—Lisinopril—coronary artery disease	0.000215	0.000327	CcSEcCtD
Apraclonidine—Nausea—Ramipril—coronary artery disease	0.000213	0.000324	CcSEcCtD
Apraclonidine—Nausea—Timolol—coronary artery disease	0.000208	0.000317	CcSEcCtD
Apraclonidine—Vomiting—Lisinopril—coronary artery disease	0.000207	0.000315	CcSEcCtD
Apraclonidine—Dermatitis—Lisinopril—coronary artery disease	0.000205	0.000312	CcSEcCtD
Apraclonidine—Headache—Lisinopril—coronary artery disease	0.000204	0.00031	CcSEcCtD
Apraclonidine—Nausea—Lisinopril—coronary artery disease	0.000193	0.000294	CcSEcCtD
Apraclonidine—ADRA2C—Signaling Pathways—RPS6KB1—coronary artery disease	2.61e-05	7.67e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—APOA1—coronary artery disease	2.61e-05	7.67e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—S100B—coronary artery disease	2.61e-05	7.67e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—POMC—coronary artery disease	2.61e-05	7.67e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CREB1—coronary artery disease	2.61e-05	7.67e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GSTM1—coronary artery disease	2.61e-05	7.66e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AGTR1—coronary artery disease	2.6e-05	7.65e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PRKCD—coronary artery disease	2.6e-05	7.64e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SOCS3—coronary artery disease	2.58e-05	7.59e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—MAPK1—coronary artery disease	2.57e-05	7.55e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—LPL—coronary artery disease	2.56e-05	7.52e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—KITLG—coronary artery disease	2.55e-05	7.5e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TGFBR2—coronary artery disease	2.55e-05	7.5e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CCL2—coronary artery disease	2.55e-05	7.5e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL6R—coronary artery disease	2.55e-05	7.48e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ITGB3—coronary artery disease	2.54e-05	7.48e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—HTR2A—coronary artery disease	2.54e-05	7.47e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CXCL10—coronary artery disease	2.54e-05	7.47e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—C3—coronary artery disease	2.54e-05	7.46e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PLG—coronary artery disease	2.54e-05	7.45e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GPX1—coronary artery disease	2.5e-05	7.34e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MMP3—coronary artery disease	2.5e-05	7.33e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—STAT5A—coronary artery disease	2.5e-05	7.33e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CXCL8—coronary artery disease	2.48e-05	7.3e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PPP2CA—coronary artery disease	2.47e-05	7.26e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ADRB2—coronary artery disease	2.47e-05	7.25e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PRKCE—coronary artery disease	2.44e-05	7.16e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—JAK2—coronary artery disease	2.44e-05	7.16e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CD36—coronary artery disease	2.43e-05	7.15e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SOCS1—coronary artery disease	2.43e-05	7.14e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PRKCD—coronary artery disease	2.43e-05	7.13e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—S100B—coronary artery disease	2.43e-05	7.13e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—HIF1A—coronary artery disease	2.42e-05	7.12e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AGT—coronary artery disease	2.41e-05	7.09e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—APOB—coronary artery disease	2.41e-05	7.09e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—AKT1—coronary artery disease	2.4e-05	7.06e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PPP2CA—coronary artery disease	2.4e-05	7.06e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SOCS3—coronary artery disease	2.4e-05	7.06e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CXCL8—coronary artery disease	2.39e-05	7.03e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—JAK2—coronary artery disease	2.38e-05	6.99e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HTR2A—coronary artery disease	2.38e-05	6.98e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EDN1—coronary artery disease	2.37e-05	6.98e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—KITLG—coronary artery disease	2.37e-05	6.97e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TGFBR2—coronary artery disease	2.37e-05	6.97e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—C3—coronary artery disease	2.37e-05	6.97e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—LEP—coronary artery disease	2.36e-05	6.95e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—APOE—coronary artery disease	2.36e-05	6.95e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCL5—coronary artery disease	2.36e-05	6.92e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—APOA1—coronary artery disease	2.34e-05	6.87e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CSF2—coronary artery disease	2.32e-05	6.82e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FGF1—coronary artery disease	2.32e-05	6.82e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MMP3—coronary artery disease	2.32e-05	6.81e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—STAT5A—coronary artery disease	2.32e-05	6.81e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—KDR—coronary artery disease	2.32e-05	6.81e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—MTHFR—coronary artery disease	2.3e-05	6.77e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—LPL—coronary artery disease	2.3e-05	6.77e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MAPK14—coronary artery disease	2.3e-05	6.76e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PPARG—coronary artery disease	2.3e-05	6.76e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MEF2C—coronary artery disease	2.28e-05	6.71e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RPS6KB1—coronary artery disease	2.28e-05	6.71e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—POMC—coronary artery disease	2.27e-05	6.67e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HIF1A—coronary artery disease	2.26e-05	6.65e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ESR1—coronary artery disease	2.26e-05	6.63e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AGT—coronary artery disease	2.25e-05	6.62e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—AKT1—coronary artery disease	2.24e-05	6.59e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APOB—coronary artery disease	2.24e-05	6.59e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—PIK3CA—coronary artery disease	2.23e-05	6.56e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—F2—coronary artery disease	2.23e-05	6.55e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—FN1—coronary artery disease	2.23e-05	6.55e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ITGB3—coronary artery disease	2.22e-05	6.54e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CXCL8—coronary artery disease	2.22e-05	6.53e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL6ST—coronary artery disease	2.22e-05	6.53e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—JAK2—coronary artery disease	2.21e-05	6.5e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—LEP—coronary artery disease	2.21e-05	6.49e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—APOE—coronary artery disease	2.21e-05	6.49e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EDN1—coronary artery disease	2.21e-05	6.48e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NFKBIA—coronary artery disease	2.2e-05	6.47e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—AGT—coronary artery disease	2.19e-05	6.43e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCL5—coronary artery disease	2.19e-05	6.43e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—APOA1—coronary artery disease	2.18e-05	6.42e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CXCL8—coronary artery disease	2.17e-05	6.38e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—KDR—coronary artery disease	2.16e-05	6.36e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PPP2CA—coronary artery disease	2.16e-05	6.35e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CSF2—coronary artery disease	2.16e-05	6.34e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FGF1—coronary artery disease	2.16e-05	6.34e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MAPK14—coronary artery disease	2.15e-05	6.32e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—APOE—coronary artery disease	2.15e-05	6.3e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—LPL—coronary artery disease	2.14e-05	6.29e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—KIT—coronary artery disease	2.13e-05	6.27e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PRKCD—coronary artery disease	2.12e-05	6.24e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RPS6KB1—coronary artery disease	2.12e-05	6.23e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MEF2C—coronary artery disease	2.12e-05	6.23e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—APOA1—coronary artery disease	2.12e-05	6.23e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ESR1—coronary artery disease	2.11e-05	6.2e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—F2—coronary artery disease	2.08e-05	6.12e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—FN1—coronary artery disease	2.08e-05	6.12e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HTR2A—coronary artery disease	2.08e-05	6.1e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL6ST—coronary artery disease	2.07e-05	6.1e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—C3—coronary artery disease	2.07e-05	6.09e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ALB—coronary artery disease	2.07e-05	6.08e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ITGB3—coronary artery disease	2.07e-05	6.07e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NFKBIA—coronary artery disease	2.06e-05	6.05e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—GSK3B—coronary artery disease	2.05e-05	6.02e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—POMC—coronary artery disease	2.03e-05	5.97e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CREB1—coronary artery disease	2.03e-05	5.97e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CXCL8—coronary artery disease	2.02e-05	5.93e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PPP2CA—coronary artery disease	2.01e-05	5.9e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—KIT—coronary artery disease	1.99e-05	5.86e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCL2—coronary artery disease	1.99e-05	5.84e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL6R—coronary artery disease	1.98e-05	5.82e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—NOS3—coronary artery disease	1.98e-05	5.81e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HIF1A—coronary artery disease	1.98e-05	5.81e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PRKCD—coronary artery disease	1.97e-05	5.79e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AGT—coronary artery disease	1.97e-05	5.79e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IGF1—coronary artery disease	1.95e-05	5.74e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—MAPK1—coronary artery disease	1.94e-05	5.71e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—LEP—coronary artery disease	1.93e-05	5.67e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—APOE—coronary artery disease	1.93e-05	5.67e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HTR2A—coronary artery disease	1.93e-05	5.67e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—C3—coronary artery disease	1.93e-05	5.66e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—GSK3B—coronary artery disease	1.91e-05	5.62e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—APOA1—coronary artery disease	1.91e-05	5.61e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CREB1—coronary artery disease	1.9e-05	5.58e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—POMC—coronary artery disease	1.9e-05	5.58e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—KDR—coronary artery disease	1.89e-05	5.56e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MAPK14—coronary artery disease	1.88e-05	5.52e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PPARG—coronary artery disease	1.87e-05	5.49e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—PIK3CA—coronary artery disease	1.86e-05	5.46e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCL2—coronary artery disease	1.86e-05	5.46e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SERPINE1—coronary artery disease	1.86e-05	5.45e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL6R—coronary artery disease	1.85e-05	5.44e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ESR1—coronary artery disease	1.84e-05	5.42e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—POMC—coronary artery disease	1.84e-05	5.42e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HIF1A—coronary artery disease	1.84e-05	5.4e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AGT—coronary artery disease	1.83e-05	5.38e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IGF1—coronary artery disease	1.83e-05	5.36e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—AKT1—coronary artery disease	1.82e-05	5.35e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FN1—coronary artery disease	1.82e-05	5.35e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—F2—coronary artery disease	1.82e-05	5.35e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—MAPK1—coronary artery disease	1.82e-05	5.34e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL6ST—coronary artery disease	1.81e-05	5.33e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PTGS2—coronary artery disease	1.81e-05	5.32e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NFKBIA—coronary artery disease	1.8e-05	5.29e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—FGF2—coronary artery disease	1.8e-05	5.28e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—LEP—coronary artery disease	1.79e-05	5.27e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APOE—coronary artery disease	1.79e-05	5.27e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APOA1—coronary artery disease	1.77e-05	5.21e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NOS3—coronary artery disease	1.77e-05	5.21e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—KDR—coronary artery disease	1.76e-05	5.16e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MAPK14—coronary artery disease	1.75e-05	5.13e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—KIT—coronary artery disease	1.74e-05	5.12e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—PIK3CA—coronary artery disease	1.74e-05	5.1e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SERPINE1—coronary artery disease	1.73e-05	5.09e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—JAK2—coronary artery disease	1.72e-05	5.06e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ESR1—coronary artery disease	1.71e-05	5.03e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—F2—coronary artery disease	1.69e-05	4.97e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FN1—coronary artery disease	1.69e-05	4.97e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—PIK3CA—coronary artery disease	1.69e-05	4.96e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL6ST—coronary artery disease	1.69e-05	4.95e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ALB—coronary artery disease	1.68e-05	4.94e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—FGF2—coronary artery disease	1.68e-05	4.93e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—GSK3B—coronary artery disease	1.67e-05	4.91e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NFKBIA—coronary artery disease	1.67e-05	4.91e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—POMC—coronary artery disease	1.66e-05	4.87e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CREB1—coronary artery disease	1.66e-05	4.87e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NOS3—coronary artery disease	1.65e-05	4.86e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCL2—coronary artery disease	1.62e-05	4.77e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—KIT—coronary artery disease	1.62e-05	4.76e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL6R—coronary artery disease	1.62e-05	4.75e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—JAK2—coronary artery disease	1.61e-05	4.73e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—NOS3—coronary artery disease	1.61e-05	4.72e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IGF1—coronary artery disease	1.6e-05	4.69e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—MAPK1—coronary artery disease	1.59e-05	4.67e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—PIK3CA—coronary artery disease	1.58e-05	4.63e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CXCL8—coronary artery disease	1.57e-05	4.62e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GSK3B—coronary artery disease	1.55e-05	4.57e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—POMC—coronary artery disease	1.54e-05	4.53e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CREB1—coronary artery disease	1.54e-05	4.53e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—AKT1—coronary artery disease	1.52e-05	4.46e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—PIK3CA—coronary artery disease	1.52e-05	4.46e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SERPINE1—coronary artery disease	1.52e-05	4.45e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCL2—coronary artery disease	1.51e-05	4.43e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CASP3—coronary artery disease	1.5e-05	4.42e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL6R—coronary artery disease	1.5e-05	4.42e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—IL6—coronary artery disease	1.49e-05	4.39e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IGF1—coronary artery disease	1.48e-05	4.36e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—MAPK1—coronary artery disease	1.48e-05	4.34e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PTGS2—coronary artery disease	1.47e-05	4.32e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CXCL8—coronary artery disease	1.47e-05	4.31e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FGF2—coronary artery disease	1.47e-05	4.31e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCND1—coronary artery disease	1.46e-05	4.3e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NOS3—coronary artery disease	1.45e-05	4.25e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MMP9—coronary artery disease	1.42e-05	4.18e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—AKT1—coronary artery disease	1.42e-05	4.17e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PIK3CA—coronary artery disease	1.41e-05	4.14e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SERPINE1—coronary artery disease	1.41e-05	4.14e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—JAK2—coronary artery disease	1.41e-05	4.13e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CASP3—coronary artery disease	1.4e-05	4.13e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—IL6—coronary artery disease	1.4e-05	4.1e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—AKT1—coronary artery disease	1.38e-05	4.05e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PIK3CA—coronary artery disease	1.38e-05	4.05e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCND1—coronary artery disease	1.37e-05	4.02e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FGF2—coronary artery disease	1.36e-05	4e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NOS3—coronary artery disease	1.34e-05	3.95e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MMP9—coronary artery disease	1.33e-05	3.9e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—JAK2—coronary artery disease	1.31e-05	3.84e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—AKT1—coronary artery disease	1.29e-05	3.78e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CXCL8—coronary artery disease	1.28e-05	3.77e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PIK3CA—coronary artery disease	1.28e-05	3.76e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—VEGFA—coronary artery disease	1.28e-05	3.75e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—AKT1—coronary artery disease	1.24e-05	3.64e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CASP3—coronary artery disease	1.23e-05	3.61e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL6—coronary artery disease	1.22e-05	3.59e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCND1—coronary artery disease	1.2e-05	3.51e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CXCL8—coronary artery disease	1.19e-05	3.5e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—VEGFA—coronary artery disease	1.19e-05	3.5e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TGFB1—coronary artery disease	1.17e-05	3.44e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MMP9—coronary artery disease	1.16e-05	3.41e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—AKT1—coronary artery disease	1.15e-05	3.38e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MAPK1—coronary artery disease	1.15e-05	3.38e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CASP3—coronary artery disease	1.14e-05	3.35e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL6—coronary artery disease	1.13e-05	3.33e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—AKT1—coronary artery disease	1.13e-05	3.31e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CA—coronary artery disease	1.11e-05	3.27e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCND1—coronary artery disease	1.11e-05	3.26e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TGFB1—coronary artery disease	1.09e-05	3.22e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MMP9—coronary artery disease	1.08e-05	3.17e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MAPK1—coronary artery disease	1.07e-05	3.15e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—AKT1—coronary artery disease	1.05e-05	3.07e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—VEGFA—coronary artery disease	1.04e-05	3.06e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CA—coronary artery disease	9.97e-06	2.93e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—VEGFA—coronary artery disease	9.68e-06	2.85e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TGFB1—coronary artery disease	9.57e-06	2.81e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MAPK1—coronary artery disease	9.38e-06	2.76e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CA—coronary artery disease	9.31e-06	2.74e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—AKT1—coronary artery disease	9.1e-06	2.67e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CA—coronary artery disease	9.04e-06	2.66e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TGFB1—coronary artery disease	8.89e-06	2.61e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL6—coronary artery disease	8.83e-06	2.59e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MAPK1—coronary artery disease	8.72e-06	2.56e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL6—coronary artery disease	8.25e-06	2.42e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AKT1—coronary artery disease	8.14e-06	2.39e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CA—coronary artery disease	8.14e-06	2.39e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AKT1—coronary artery disease	7.61e-06	2.24e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CA—coronary artery disease	7.56e-06	2.22e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—AKT1—coronary artery disease	7.39e-06	2.17e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL6—coronary artery disease	7.21e-06	2.12e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL6—coronary artery disease	6.7e-06	1.97e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AKT1—coronary artery disease	6.65e-06	1.95e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AKT1—coronary artery disease	6.18e-06	1.82e-05	CbGpPWpGaD
